An Analysis of Vaccine Rollout During the COVID-19 Pandemic

In 2019 a pneumonia-like disease appeared in China and began to spread globally, infecting hundreds of thousands and resulting in the deaths of tens of thousands. This disease, COVID-19 (Coronavirus disease 2019), became one of the deadliest pandemics in recent history. Many countries attempted to curb its spread through primary prevention measures such as social distancing and masking, the spread only reached a stopping point when the creation of a COVID-19 vaccine was completed. Once widespread vaccination became widespread, these vaccines significantly reduced the severity of symptoms and the need for hospitalization. Currently, many countries report fewer than 5,000 active cases of COVID, with only a small percentage of those infected needing further hospitalization. Despite the remarkable development of COVID-19 vaccines, the global rollout encountered considerable challenges, including logistical inefficiencies, uneven distribution, and variations in infrastructure, etc. To fill this gap, this study investigates and compares vaccine development and rollout strategies adopted by various countries, with the goal of identifying effective models and areas for improvement. Insights drawn from this analysis are instrumental for developing infrastructure to defend against a future pandemic scenario, informing the design of more resilient, equitable, and responsive systems for future global health emergencies.